Podcasts about Echelon

In this episode Frank and Mere explore the possibilities of taking the podcast on the road. Would it be an epic adventure or an epic fail? Who would drive? Who controls the radio? Can Mere visit all the roadside attractions or is Frank a meanie? We (Mere) had many technical difficulties which Frank has handled masterfully to bring you this fun-filled episode. Mere also reviews the Bed & Breakfast where she has been residing for the past couple of weeks and of course there are pupdates and some Echelon news for you all as well! Enjoy!

Governor Gavin Newsom continued to fall in nationwide 2020 Presidential candidate polling this week, with the most recent Echelon poll giving him only 5% of the vote. May 13th 2025 --- Please Like, Comment and Follow 'The Ray Appleton Show' on all platforms: --- 'The Ray Appleton Show’ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. --- 'The Ray Appleton Show’ Weekdays 11 AM -2 PM Pacific on News/Talk 580 AM & 105.9 KMJ | Website | Facebook | Podcast | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

The Taoiseach Micheál Martin today described two large-scale data centre facilities being developed by Echelon Data Centres in Co Wicklow as "the model for future data centre development in Ireland". Speaking in Arklow at the official launch of Echelon Data Centres' DUB20 and DUB30 facilities, the Taoiseach provided strong support for the data centre sector and the economic value it delivers for Ireland. Mr Martin said: "These two large-scale facilities demonstrate Echelon's commitment to responsible data centre development. They are located in a regional area where the grid isn't constrained, they will have the capacity to generate and dispatch power to the grid when needed, and they will facilitate the generation of renewable energy resources that will, in turn, help decarbonise Ireland's electricity system. "They are the model for future data centre development in Ireland - and they will deliver jobs and economic benefits for Wicklow, and will encourage further foreign direct investment in Ireland. CEO of IDA Ireland, Michael Lohan added: "Driving sustainable change sits at the very heart of IDA Ireland's Adapt Intelligently: A Strategy for Sustainable Growth and Innovation 2025-29. Indeed, our client companies are instrumental in shaping a green and digital global economy. Echelon's commitment to operating its facilities sustainably, responsibly, and with due regard for the environment is commendable. I wish the team continued success." Echelon will invest an estimated €3.5bn to develop the DUB20 & DUB30 sites, creating around 2,600 jobs during construction and 715 permanent positions at the two facilities once they are operational. However, an Economic Impact Assessment report prepared for Echelon by KPMG has calculated that the potential economic output of the DUB20 and DUB30 sites could be as much as €7.5bn during the construction phase, and €801m per year once both campuses are operational. The Economic Impact Assessment states that the potential economic output of the DUB20 and DUB30 sites could be as much as €7.5bn during the construction phase, and €801m per year once both campuses are operational. The report found that every €1 Echelon invests in the DUB20 and DUB30 sites could yield a return of €1.60 due to additional economic activity through supply chains and employee spending across construction and operational phases. It also found that for every 10 jobs created during construction, up to nine additional jobs will be supported elsewhere in the economy, while every 10 direct operational roles could sustain a further 16 jobs. Echelon Chief Operations Officer, Graeme McWilliams said: "Echelon's sites in Wicklow will generate broad-based economic value with measurable impact across the Irish economy that goes far beyond our initial investment. They represent responsible data centre development which supports regional development and job creation in partnership with good grid citizenship. "The energy demands of DUB20 and DUB30 will underpin investment in almost 1GW of wind-generated renewable energy, power that will help reinforce the national grid, increase Ireland's energy security, and support our transition from fossil fuels to clean, green energy sources." Echelon's DUB20 campus is being developed on the site of the former Irish Fertilisers Industries plant at the Avoca River Business Park in Arklow. DUB30 is being developed some 5km away at Kish Business Park. Last year, DUB20 became the first large-scale data centre in Ireland to receive a grid connection from EirGrid for more than four years. This reflects the fact that the site meets Commission for the Regulation of Utilities' (CRU) 2021 criteria for data centre connections. The grid connection will allow Echelon to begin work on a 220kV substation at the site that will allow access to the grid for up to 800MW of wind energy generated off the coast of Wicklow in the future. Echelon is also investing in solar, battery energy storage systems, and renewabl...

May 7, 2025 ~ Chef Joseph Van Wagner, Executive Chef, Managing Partner Echelon Kitchen joins Paul live from Bamboo in Ann Arbor for the Pure Michigan Tour.

Frank and Mere get a new podcast co-host and Remy gets a new bestie. We catch up on the latest Echelon news the good, the bad, and the ugly. Mere is moving…still. There is much to discuss!

Frank and Mere hop across the pond for an interview with Echelon Instructor, Marilena Schnorrenberg, of the London Studio! Delightful banter and deep discussion of cakes ensues! We learn some ways to reframe our thinking to reach our goals and feel better while we sweat together. There is a lot of travel talk for a show about a Bike That Goes Nowhere, but seems to take us everywhere! Enjoy!

Bloopers, Barre, and Big Babies-Oh my! This episode has a little something for everyone. We catch up on moving news, discuss new class types and programs available on Echelon, provide Pupdates and review several of our favorite TV shows and podcasts. Enjoy!

Frank and Mere talk to the reigning queen of high energy dance fun, Lindsay Kaplan. She is not only a Miami Instructor, but Head of Talent for Echelon. We talk about all things Echelon, volunteering for dog rescues, photography, a possible new career as a DJ, and running in costumes. You won't want to miss this one!

The Joint Readiness Training Center is pleased to present the ninety-sixth episode to air on ‘The Crucible - The JRTC Experience.' Hosted by the Task Force Senior for the BDE Command & Control (BCT HQ), LTC Timothy Price on behalf of the Commander of Ops Group (COG). Today's guests are the notorious “Geronimo 06,” LTC Mason Thornal, and a seasoned Observer-Coach-Trainer across the fire support enterprise at the JRTC, CW3 Jerrad Rader. LTC Mason Thornal is the Battalion Commander of 1-509th IN (OPFOR). CW3 Jerrad Rader is the Brigade Targeting Officer OCT for BC2 (BCT HQ) with seventeen rotations as an OCT. In this episode, we focus on the integration and employment of small unmanned aircraft systems (sUAS) at echelon during large-scale combat operations (LSCO). The conversation explores how sUAS platforms—ranging from short-range quadcopters to medium-range reconnaissance systems—are increasingly prevalent across formations, including at the squad, company, and battalion levels. While these tools enhance battlefield transparency and ISR (intelligence, surveillance, reconnaissance) capabilities, they also introduce significant challenges in areas such as target identification, airspace deconfliction, and command and control. Rather than solving new problems, sUAS platforms are reframing existing warfighting challenges with different tools and at new echelons, placing additional emphasis on defining authorities, refining standard operating procedures (SOPs), and ensuring operators understand their role within the broader targeting process.   The episode also highlights best practices and points of friction in employing sUAS across the force. A major issue is the lack of standardized processes and knowledge management systems to handle the influx of information generated by sUAS. Brigades must move beyond simply acquiring new platforms to fully integrating them into the targeting cycle, using tools like targeting synchronization matrices and engagement criteria. Proficiency and training are recurring themes—highlighting that operator skill can be the difference between mission success and failure. The episode concludes by urging leaders to invest in home station training, share lessons learned across units, and foster innovation at the lowest levels, reinforcing that success with sUAS in LSCO will come from disciplined process integration, not just hardware acquisition.   Part of S04 “Scouts Out” series.   For additional information and insights from this episode, please check-out our Instagram page @the_jrtc_crucible_podcast   Be sure to follow us on social media to keep up with the latest warfighting TTPs learned through the crucible that is the Joint Readiness Training Center.   Follow us by going to: https://linktr.ee/jrtc and then selecting your preferred podcast format.   Again, we'd like to thank our guests for participating. Don't forget to like, subscribe, and review us wherever you listen or watch your podcasts — and be sure to stay tuned for more in the near future.   “The Crucible – The JRTC Experience” is a product of the Joint Readiness Training Center.

Frank and Mere get the scoop from Audrey Johnson on how she stays sane, which piece of Echelon equipment is her favorite, what is was like visitng Chattanooga, and winning a Run Disney race entry as well as a stay at Animal Kingdom! How did she end up in the front at the starting line? How much does her family love her for winning that prize? We also figure out how we can all add more Echelon equipment to our homes and Mere has some great tips!

Join Frank and Mere as they catch up Echelon news, pupdates, past episodes, and what to watch. Get answers to age old questions like, "Would Mere move to Arizona just to get out of Daylight Savings Time?" and "Does Remy like potato chips?" Plus, learn a couple of interesting tidbits about the hosts as they go off script with reckless abandon. It's all in good fun!

The Joint Readiness Training Center is pleased to present the ninety-fourth episode to air on ‘The Crucible - The JRTC Experience.' Hosted by COL Ricky Taylor, the Commander of Ops Group (COG). Today's guest is a familiar face on The Crucible, the former Command Sergeant Major of Ops Group (CSMOG), CSM Michael Hall.   This episode explores the evolving role of non-commissioned officers (NCOs) in large-scale combat operations (LSCO), with a special emphasis on the sergeant major's critical influence on unit discipline, readiness, and execution. Discussions highlight the transition from counterinsurgency to LSCO, emphasizing how the Army is adapting to the realities of high-intensity warfare. The conversation underscores the importance of disciplined formations, accountability, and a strong combat mindset, which sergeant majors play a central role in fostering. The episode also delves into leadership at echelon, emphasizing the need for NCOs to hold each other accountable and build a culture of excellence through rigorous training and adherence to the fundamentals.   A significant portion of the discussion focuses on the involvement of sergeant majors in planning and execution, particularly in mitigating risk, ensuring mission success, and developing junior leaders. The conversation explores how NCOs can better integrate into mission analysis, wargaming, and staff planning to enhance operational effectiveness. Additionally, the importance of battlefield circulation, command presence, and real-time decision-making is emphasized, with insights on how sergeant majors can alleviate command anxiety by identifying and addressing points of friction. The episode concludes with a strong call for NCOs to instill a combat-ready culture through meticulous training, trust-building, and fostering pride in the profession, ensuring formations are prepared for the challenges of LSCO.     Part of S02 “If I Would Have Only Known” series.     For additional information and insights from this episode, please check-out our Instagram page @the_jrtc_crucible_podcast   Be sure to follow us on social media to keep up with the latest warfighting TTPs learned through the crucible that is the Joint Readiness Training Center.   Follow us by going to: https://linktr.ee/jrtc and then selecting your preferred podcast format.   Again, we'd like to thank our guests for participating. Don't forget to like, subscribe, and review us wherever you listen or watch your podcasts — and be sure to stay tuned for more in the near future.   “The Crucible – The JRTC Experience” is a product of the Joint Readiness Training Center.

Frank and Mere talk with Echelon community member and human extraordinare, Justin Kees. Are his legs insured? How many baseball cards does he have? Why is he turning the tables and questioning the hosts? So much fun talking about baseball, spreading positivity through Jamming with Justin, riding to the moon, and working toward goals.

In this conversation, Scott McGill shares insights into his cycling career, training regimen, and the balance between personal life and professional commitments. He discusses his early riding habits, the importance of versatility in racing, and the significance of consistency in training. Scott also delves into specific workouts, sprinting techniques, and how he manages to maintain a balance between his athletic pursuits and personal interests.Thanks, Scott! Find him on IG here:https://www.instagram.com/scottmcgilljr/Chapters:0:32 Welcome!01:00 Training Philosophy05:00 Strength and Conditioning12:30 Race Preparation30:30 Pro Race Intensity and Accumulation of Efforts32:30 Nutrition and Heat Training38:00 Underrated Training Aspects42:00 Racing Tactics45:30 Early Career Advice47:30 Equipment and Aerodynamics51:30 Career Goals and Mindset

Live from the Battle Born Broadcast Center, legal insider Justin Watkins joins Cofield & Company to review the significance of Tom Brady meeting up with Matthew Stafford at a ski resort in Montana, San Diego State Athletic Director statement on the timeline for the new PAC-12 conference television deal, and give his legal insight into reports of an inside gambling ring linked to point shaving across pro and college basketball. The Michael Jackson estate's successful lawsuit against HBO for a hit piece against Michael Jackson. CEO of the Sporting Tribune, Arash Markazi joins Cofield & Co. to review Kelly Stafford's comments on Matthew Stafford's contract dispute with the Los Angeles Rams, recap Luka Doncic's first game against the Dallas Mavericks as a Los Angeles Laker, and detail the overall reaction to the Los Angeles Lakers' dedication video for Anthony Davis ahead of the Lakers' match up against Dallas.  

Join Frank and Mere for a delightful conversation with Echelon Rider, Strider, Rower, and Fitpasser, Kami Young! Learn valuable tips for outdoor riding and bike commuting, hear how Kami and her family made history in the best way, and find out Buddy's origin story. We delve into a major health issue that Kami faced and her experiences with all that was involved including an Echelon comeback.After the interview, Frank and Mere discuss pupdates and TV, along with an enthralling tale about a Donut Run!Thanks for listening!

Our remarkable guest from Season One returns explaining how a small group of powerful men create celebrities out of abused children:Anneke Lucas was only a small child growing up in a little town in Belgium, when her mother began taking her to adult parties, and trafficking her to be abused as part of an organized system. When she was nine, she was spotted at one of these events by none other than David Rockefeller, who made her his own special project, whisking her away to America and presenting her as his ‘niece.' Presented to David's superior in the group, Sir Evelyn Rothschild, Anneke was invited to “join the family,” pledge her soul, and began preparing for her designated role as a future singing star. This training included not only music and dance lessons, but mental conditioning during a stint in the MK Ultra program in Germany, where she was tortured in order to prep her for her ‘real' career– spying on the powerful men with whom Rockefeller ‘shared' her. Anneke ultimately rejected the plan that had been set for her, and had to endure the torture inflicted for her disobedience.Anneke now enjoys a thriving life and her own podcast. She shares her story in hope that someday no child will endure this type of experience.Heroes Behind HeadlinesExecutive Producer Ralph PezzulloProduced & Engineered by Mike DawsonMusic provided by ExtremeMusic.comDesperately Seeking the '80sRevisit the crime and culture of NYC in the '80s with BFF Gen-Xers Jessica and Meg.Listen on: Apple Podcasts Spotify

Frank Truong and Meredith Willis head up this new season of the podcast. We're bringing new segments including pupdates and have a list of Echelon community, instructors, and team members a mile long to interview.This episode reminds you a little bit about who we are (Frank & Mere) and why we're doing this (we're mad for all things Echelon). Many thanks to Sheldon Young for re-recording our amazing theme song that he wrote, played, and sang and to Abe Kelledjian for helping us get up and running and assisting us with publishing!This podcast is truly a team effort and YOU the community are part of that team! Thank you for joinging us on this amazing journey and we'll try to keep the workout words to a minimum!

Rob and Jeremy took some time from the second hour of Tuesday's BBMS to debate where Jalen Hurts falls in the pecking order of the NFL's quarterbacks. Does a Super Bowl win vault him into the top five with Lamar Jackson, Joe Burrow, and Patrick Mahomes?

Echelon Data Centres is an international data centre infrastructure developer providing large-scale assets to support the growing global demand for data and computing resources – sustainably, responsibly and with due regard for the environment. It currently has six facilities in Ireland and the UK – either online or under development – with a combined potential capacity of around 800MW. Their infrastructure is responsibly designed, sustainably powered and allied to Echelon's ongoing investment in renewable and alternative power sources. Infrastructure that is built and managed sustainably and ethically, recognising their responsibilities to the people and partners they work with, the communities where they operate, the society they are a part of, and the planet we all share. Niall Molloy , CEO and founder of Echelon Data Centres. He is also Managing Director of Aldgate Developments. A qualified Chartered Accountant with a strong background in banking and finance, Niall is highly experienced in commercial property development and has a proven track record of successfully delivering large-scale, complex projects on time and within budget while driving returns for investors. As CEO, Niall is responsible for the strategic direction of Echelon Data Centres and takes an active role in all aspects of property selection, assessment, delivery and operations. This is the 45th episode with guest Niall Molloy, CEO of Echelon Data Centres, in the Davy podcast series 'Everyday Business with Aidan Donnelly'.

Jeremy Au referenced Asia Partners' report predicting a surge in Southeast Asian unicorns based on macroeconomic fundamentals, and discussed the GDP per capita “time machine” phenomenon where Chinese and American founders enter Southeast Asia to replicate proven business models in frontier markets. He also shared an LP's perspective on Southeast Asia's underperforming VC funds, questioning whether it was due to fund selection or broader market dynamics, e.g. Vietnam's struggle to produce a successful tech IPO and high U.S. interest rates that have constrained regional Series B/C capital. He compared VCs to Olympic coaches, explaining that top investors prioritize 10x teams, product, and defensible economics—but competition is fierce for the best startup teams, e.g. Rewind AI receiving 170 term sheets via a Google form auction as an extreme case of a bidding war where VCs fight to get into the round. === Jeremy Au (区汉辉) hosts BRAVE Southeast Asia Tech, the region's #1 tech podcast and global top 10% podcast with 50,000+ monthly listeners. He cofounded Orvel Ventures (network-driven VC fund), leads the Harvard Business School Alumni Angels for Southeast Asia and is an angel investor in 24 startups. Jeremy teaches venture capital fund strategy and entrepreneurship at National University of Singapore and Singapore Management University. Previously, Jeremy was a VC investor and Chief of Staff at Monk's Hill Ventures, Southeast Asia's leading pre-A and Series A investor. Jeremy founded and led CozyKin, an early education marketplace to Series A and acquisition by Higher Ground Education. The startup was recognized for winning Harvard Business School's New Venture Competition and the MassChallenge grand prize. Jeremy also cofounded and bootstrapped Conjunct Consulting, an impact consulting platform, to profitability, 100+ clients and thousands of trained impact leaders. He was a Bain management consultant and an infantry sergeant in Singapore. Jeremy is a keynote public speaker on entrepreneurship, leadership and community engagement for thousands across Harvard, Deutsche Bank, e27 Echelon, Singapore Global Tech Network, Boston SPARK Council, Institute of Policy Studies, Civil Service College and many others. Recognized by Forbes 30 Under 30, Prestige 40 Under 40 and LinkedIn Top Voice. Author of BRAVE10, showcasing the top 10 journeys of Singapore tech leaders. Harvard MBA and UC Berkeley honor degrees in Economics & Business Administration. Jeremy enjoys science fiction, hiking and being a dad of two daughters. === Watch, listen or read the full insight at https://www.bravesea.com/blog/gdp-per-capita-time-machine Get transcripts, startup resources & community discussions at www.bravesea.com WhatsApp: https://whatsapp.com/channel/0029VakR55X6BIElUEvkN02e TikTok: https://www.tiktok.com/@jeremyau Instagram: https://www.instagram.com/jeremyauz Twitter: https://twitter.com/jeremyau LinkedIn: https://www.linkedin.com/company/bravesea Spotify English: https://open.spotify.com/show/4TnqkaWpTT181lMA8xNu0T Bahasa Indonesia: https://open.spotify.com/show/2Vs8t6qPo0eFb4o6zOmiVZ Chinese: https://open.spotify.com/show/20AGbzHhzFDWyRTbHTVDJR Vietnamese: https://open.spotify.com/show/0yqd3Jj0I19NhN0h8lWrK1 YouTube English: https://www.youtube.com/@JeremyAu?sub_confirmation=1 Apple Podcast English: https://podcasts.apple.com/sg/podcast/brave-southeast-asia-tech-singapore-indonesia-vietnam/id1506890464 #VentureCapital #StartupFunding #SoutheastAsiaTech #PowerLawReturns #UnicornHunting #TechInvestments #InnovationEconomy #EntrepreneurshipInsights #TechGrowth #BRAVEpodcast

In this edition of the pod, Matt and David dive deep into the world of Saucony running shoes. They discuss the brand's popular daily trainers, like the Ride and Triumph, known for their comfort and versatility. Next, they explore stability models, such as the Guide and Hurricane. Then the reach for speed with the Endorphin line, featuring the Trainer, Speed, Pro, and Elite (and Sinister, though not technically an "Endorphin" shoe). Finally, Matt and David discuss a few of their trail offerings for when you're ready for some off-road action. What's your favorite Saucony shoe? Let us know at doctorsofrunning@gmail.com! Get your DOR Merch: https://doctors-of-running.myspreadshop.com/ Check out our friends at ⁠⁠⁠⁠⁠⁠Skratch⁠⁠⁠⁠⁠⁠ and save 25% on your first order with code DOR24! Chapters 0:00 - Intro 5:04 - Saucony's daily trainers (Ride, Triumph) 15:08 - Saucony's stability models (Guide, Hurricane, Omni, Echelon) 30:56 - Saucony's Endorphin line (Trainer, Speed, Pro, Elite, Sinister) 57:12 - Saucony's trail shoes

From the top of one of the tallest points in Arizona we join our hero, Tyler Stites, as he prepares to set out on a new journey across the ocean to a fulltime spot in the European peloton. For the last 3 seasons we've got to enjoy his racing on Project Echelon but now he's signed a two-year deal with Caja Rural and he's ready to spread his wings. Before he does, we got a chance to talk with him about where he's been and how he's enjoyed the ride along the way. This week we are brought to you by the Hammerhead Karoo. Visit hammerhead.io right now and use promo code CRITNATION at checkout to get yours today! By using the code CRITNATION you'll get a free heart rate monitor with your purchase of a Karoo. Go to Hammerhead.io today, add both items to your cart, and the HR monitor is on us! We are also brought to you by Properties on the Potomac, the boutique real estate firm for all your needs in Northern Virginia, Washington, and Maryland. Check them out at PotPhomes.com.

How do the Texans 'stack up' when measured up against THIS week's opponent-the Miami Dolphins?

My initial thoughts on these 2 excellent handguns. Patreon Support Amazon Store Music by Ozark Revival, “You Aint Gettin My Guns” on Youtube.

Por muitos anos ufólogos do mundo denunciaram a existência de um projeto altamente secreto destinado à escuta clandestina de ligações telefônicas, chamado Echelon. Com base nas poucas informações secretas vinda à público, o sistema Echelon poderia ter acesso à quase todos as ligações telefônicas feitas no mundo, à maioria das transmissões de fax, que era muito utilizado na época e depois, com o surgimento da Internet monitorando também os e-mails de pessoas de interesse da inteligência dos Estados Unidos Então apertem o play , e sejam monitorados ao escutarem o episódio ! RECOMENDAMOS ESCUTAR COM FONES DE OUVIDO Se você gosta do nosso trabalho, contribua com o apoia-se  e participe do nosso grupo exclusivo para apoiadores ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apoia-se Acredite se Quiser Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apoia-se Portal Fenomenum⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon Acredite se Quiser⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Siga e avalie o Acredite Se Quiser nas plataformas de streaming! Siga-nos nas redes sociais: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Pré venda livro Relatos Alienígenas na Amazon ⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠E-mail para contato: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠acreditesequiserpodcast@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Conheça a nova loja SkynWalker na Reserva Ink⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Links citados no episódio: Canal Fenomenum - Sorria: Você está sendo monitorado!

Resting up after the Thanksgiving indulgence? Making the trip back home? Whatever it is, you'll probably enjoy it more if you're listening to this trio of savvy, SE MI wine biz luminaries with their thoughtfully piloted discussions laced with both humor and gravitas. Maria owns SimplyWine in Northville; Taylor is beverage director at the upcoming Echelon restaurant in Ann Arbor; Kat is in wholesale wine sales with Decanter & Coupe. Maybe it's their complementary experiences, but we tend to think the magic is that thoughtful people are just really interesting!Dial this one up on Apple Podcasts or Spotify, and enjoy the discussion!

In Episode 59 of the Virtual Velo Podcast, Chris and Emma welcome Eric Hill, founder of Project Echelon Racing and Echelon Racing Promotions. Eric has been a visionary in blending traditional cycling with virtual racing, supporting the sport and the veteran community through his groundbreaking initiatives. In this episode, we'll dive into Project Echelon's mission and its impact on cycling and veterans, explore Eric's early adoption of cycling esports as a distinct discipline, and hear about his plans for the 2024/25 Echelon Racing League season. From the race schedule and prize purse to its potential role in qualifying for the 2025 USA Cycling Esports Nationals, there's a lot for racers and fans to get excited about. We'll also discuss Eric's move to MyWhoosh as the platform of choice for the upcoming season, his thoughts on performance verification, and how he plans to address athlete concerns about adapting to new technologies. Plus, he'll share details about an exciting new partnership with indieVelo—now Training Peaks Virtual.   Don't miss out on the unique opportunity to delve even deeper into the intriguing topics discussed in this episode. We've curated a selection of articles that inspired our conversation, providing you with exclusive insights. Wahoo RGT and Project Echelon Introduce Trikes For Disabled Virtual Cyclists [Zommunique, Dec. 12, 2022] One of The Most Momentous Events in Virtual Cycling Recently Took Place, and Not Enough of Us Are Aware, But We All Should Be! [Zommunique, Feb, 7, 2022] Why introducing handcycles is Zwift's most important update so far [Cycling Weekly, Oct. 10, 2022] RGT leads the charge for inclusion of disabled athletes in virtual cycling [CyclingNews, Feb. 7, 2022]   Join us for a conversational ride where we not only lend a voice to the digital athlete but also bridge the gap between athlete and avatar. We invite you to be part of this exciting exploration of the future of virtual sport and digital athlete engagement!

If you had a health condition, you would go to a surgeon or a specialist. But many business owners and entrepreneurs in this country are trying to do it themselves. That's why I brought on Chris Wilbratte, the co-founder of Echelon Financial.

Joining me now in studio are three people involved with Echelon Wellness - that the clinic that has recently opened in Mount Pearl to offer serivces to military and RCMP Veterans

In this episode, we dive into the management of older adults with Hodgkin Lymphoma with Dr. Andrew Evens. Here are the key articles we discussed: 1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: https://pubmed.ncbi.nlm.nih.gov/30179569/4. SWOG S1826 trial (Nivo-AVD vs AAVD in advanced stage classical HL): https://pubmed.ncbi.nlm.nih.gov/39413375/5. S1826 outcomes in older adults: https://ash.confex.com/ash/2023/webprogram/Paper180114.html6. Single-agent BV for older adults with Hodgkin: https://ashpublications.org/blood/article/142/Supplement%201/4435/503453 

How does someone create a podcast show that's #1 in the tech category within Southeast Asia's tech (and top 10% globally) and garners 60,000+ listeners… On top of multiple other roles and identities (such as being the COO at Lucence, a father of two, and an avid science fiction nerd)? That is a glimpse into the conversation we had with Jeremy Au about on episode 187 of The Thought  Leader Club Podcast as part of the “Work in Progress” series. Topics we touch on include: The craft of podcasting and Jeremy's thought process behind his podcast episodes  Self-awareness is critical for both podcasting and building thought leadership Don't podcast just because you want to podcast… Podcast because you want to be a nerd in a subject matter    Enjoy :)   About Jeremy: Jeremy Au (区汉辉) is the COO of Lucence, the leading biotech AI startup fighting cancer with precision oncology tests and backed by Openspace, Heliconia and IHH Healthcare. He also hosts BRAVE, Southeast Asia's #1 tech podcast and global top 10% podcast with 60,000+ monthly listeners. He co-founded Orvel Ventures (network-driven VC fund), leads the regional chapter of Harvard Business School Alumni Angels and is an angel investor in 24 startups. Harvard MBA and UC Berkeley honor degrees in Economics & Business Administration. Recognized by Forbes 30 Under 30, Prestige 40 Under 40 and LinkedIn Top Voice. Previously, Jeremy was a VC investor and Chief of Staff at Monk's Hill Ventures, Southeast Asia's pioneer Series A fund. Jeremy founded and led CozyKin, an early education marketplace, to Series A and acquisition by Higher Ground Education. The startup was recognized for winning Harvard Business School's New Venture Competition and the MassChallenge grand prize. Jeremy also co-founded and bootstrapped Conjunct Consulting, an impact consulting platform, to profitability, 100+ clients and thousands of trained impact leaders. He was a Bain management consultant and an infantry sergeant in Singapore. Jeremy is a keynote public speaker on entrepreneurship, leadership and community engagement for thousands, e.g. Harvard, Deutsche Bank, e27 Echelon, Singapore Global Tech Network, Boston SPARK Council, Institute of Policy Studies and Civil Service College. Author of BRAVE10, showcasing the journeys of Singapore's top tech leaders. Jeremy volunteers by teaching VC fund strategy and entrepreneurship at National University of Singapore and Singapore Management University. Jeremy enjoys science fiction, hiking and being a father to his two daughters.   Connect with Jeremy: www.bravesea.com www.lucence.com   

Hour 1 of the Killer B's with Joel Blank, and Jeremy Branham featured... Texans proved they belong in the upper echelon of the NFL Ka'imi already was, but has ended all debate, he's the greatest kicker in Texans' history Joel was super impressed with how Azeez Al-Shaair played yesterday, the impact he's made, and called him the Texans best offseason acquisition And lastly, we didn't ignore in victory what we wouldn't in defeat from yesterday's Texans-Bills game

We drill into the world of oil and gas exploration with Andrew Jefferies, Chief Executive of Echelon.  Andrew shares why  the company has left  the NZX for the ASX and its rebrand from NZ Oil and Gas to Echelon. He discusses the impact of the former government's decision on banning oil and gas exploration, and Echelon's decision to invest now that decision has been reversed.  While more investors demand an ESG (environmental, social and governance) approach to investing, we hear about the balance between transitioning to cleaner energy sources and meeting global energy demands. For more or to watch on youtube—check out http://linktr.ee/sharedlunch Investing involves risk. This episode is brought to you by Sharesies Australia Limited (ABN 94 648 811 830; AFSL 529893) in Australia and Sharesies Limited (NZ) in New Zealand. Information provided is general only and current at the time and does not take into account your circumstances, objectives or needs. We do not provide recommendations and you should always read the disclosure documents available to the product's issuer before making a financial decision. Our disclosure documents, including a Target Market Determination for Sharesies, can be found on our website. If you require financial advice, you should consider speaking with a qualified financial advisor. The views expressed by individuals are their own and Sharesies does not endorse any of the guests or the views they hold.See omnystudio.com/listener for privacy information.

The Joint Readiness Training Center is pleased to present the seventy-first episode to air on ‘The Crucible - The JRTC Experience.' Hosted by the former Commander of Ops Group (COG), COL Matthew Hardman. This will be his last episode to host, but we may seem him as a guest in the future. Today's guests are two key members from 2nd Battalion, 130 Infantry Regiment, MAJ Edward Worman and SGT Stephanie Smith. MAJ Worman is the Battalion Commander for 2-130th IN and SGT Smith is the S-2 Intelligence Section Non-Commisioned Officer-in-Charge.   The 2nd Battalion of 130th Infantry Regiment is an infantry regiment in the Illinois Army National Guard. 2-130 IN has an extensive and illustrious history dating back to the War of 1812. Since its establishment, the battalion has served in every conflict that the US Army has participated in, from the Mexican War to the Civil War to Indian Wars of the American Frontier to battlefields of World War I to the island hoping campaign in the Pacific Theater of World War II to the various conflicts of the Cold War and finally in support of the Global War on Terror. They are one of the infantry battalions for the 33rd Infantry Brigade Combat Team, formerly the 66th Infantry Brigade Combat Team, but for their rotation at the JRTC they were attached to the 32nd IBCT of the Wisconsin ARNG. They have the Hollywood call-sign of “Blackhawks,” the nickname of “Fourth Illinois,” and the motto of “Always Ready.”   In this episode we discuss the lessons learned at the battalion echelon for conducting large scale combat operations across multiple domains. Specifically, we focus on the information requirements for the battalion commander and his subordinate company commanders as well as best practices of an efficient battalion staff. At the battalion echelon, the commander needs timely and accurate reporting; tactical patience; and understand where leaders need to be on the battlefield. Battlefield circulation is critical during transitions between various phases of the operation. Smart-books and the TRADOC G-2 World Equipment Guide (WEG) are your friend. Staff sections should update and maintain their overlays to provide the commander with updated graphics to make decisions, such as modified combined obstacle overlay and threat overlays plus event matrix. The most successful battalions at the JRTC are those that don't overly rely on digital products and instead use analog products. Remember, to be detected is to be targeted is to be killed.   The number one question that commanders and staff ask across the force is how can we get better at the military decision making processes (MDMP)? There's no shortcut, it's simply sets and repetitions that make staffs better at MDMP. While both our guests did exceptionally well during their crucible rotation, it is nearly certain that some may feel that it is unrealistic that such junior leaders would fill those roles. We at the JRTC would argue that the opposite is true as it should be expected that large scale combat operations would inflict a high attrition rate upon our forces, demanding junior leaders to fill the void.   Part of S02 “If I Would Have Only Known” series.   For additional information and insights from this episode, please check-out our Instagram page @the_jrtc_crucible_podcast   Be sure to follow us on social media to keep up with the latest warfighting TTPs learned through the crucible that is the Joint Readiness Training Center.   Follow us by going to: https://linktr.ee/jrtc and then selecting your preferred podcast format.   Again, we'd like to thank our guests for participating. Don't forget to like, subscribe, and review us wherever you listen or watch your podcasts — and be sure to stay tuned for more in the near future.   “The Crucible – The JRTC Experience” is a product of the Joint Readiness Training Center.    

The Joint Readiness Training Center is pleased to present the sixty-ninth episode to air on ‘The Crucible - The JRTC Experience.' Hosted by the former Commander of Ops Group (COG), COL Matthew Hardman. Today's guest is the deputy senior mentor at the Leader Training Program at the JRTC, COL(R) Mike Kershaw.   He spent 34 years on active duty as an infantry officer and has been with the Leader Training Program for nearly nine years. The Leaders Training Program at the JRTC is a ten-day planning conference providing commanders and staff an opportunity to hone their military decision-making process skills and systems. The program is facilitated by retired, senior military planning coaches giving units best practices and lessons learned from previous iterations. Be sure to checkout Mike's other episode, Ep. 45 “Trends & Best Practices at Echelon within the Infantry Battalion.”   In this episode, we dive into the necessity of the modern combat leader to be both well-read and well-written. Reading a wide variety of subjects, especially historical vignettes, is crucial for military practitioners and combat leaders. These narratives offer invaluable insights into the successes and failures of others, providing lessons that can shape decision-making in complex situations. By studying diverse experiences, leaders gain perspective on strategy, tactics, and human behavior in conflict, learning to anticipate challenges and respond more effectively. Writing about these lessons is equally important, as it allows leaders to give back to their profession, sharing knowledge, refining thought processes, and contributing to the collective wisdom that strengthens future generations of military leadership.   Part of S01 “The Leader's Laboratory” series.   For additional information and insights from this episode, please check-out our Instagram page @the_jrtc_crucible_podcast   Be sure to follow us on social media to keep up with the latest warfighting TTPs learned through the crucible that is the Joint Readiness Training Center.   Follow us by going to: https://linktr.ee/jrtc and then selecting your preferred podcast format.   Again, we'd like to thank our guests for participating. Don't forget to like, subscribe, and review us wherever you listen or watch your podcasts — and be sure to stay tuned for more in the near future.   “The Crucible – The JRTC Experience” is a product of the Joint Readiness Training Center.

In this episode, we speak withAmie Teske, a health tech sales professional and advisor and founder of The Echelon. Amie shares her experience in the industry and discusses her work with building the Echelon, a community for health tech sales professionals. She emphasizes the importance of keeping sales teams focused and productive, and highlights the need for leaders to prioritize their people. Amie also discusses the power of referrals and the impact of being present with your team. She concludes by discussing the challenges of managing growth expectations and the importance of realistic goal-setting. In this conversation, Amie discusses the importance of aligning the goals of the sales team with the individual motivations of the team members. She emphasizes the need for sales leaders to triangulate what people say, what they do, and what they want in order to create achievable goals. Amie also highlights the importance of breaking down the sales numbers and creating a story that balances the expectations of the board with the motivators of the team. She emphasizes the need for strong sales operations teams and the value of building relationships with board members and investors.

Art Bell - Mike Heiser, Grant Jeffrey - Bible Code Debate. David Ruppe - Echelon

Conservative pollsters Dr. Frank Luntz and Kristen Soltis Anderson return to discuss how the election dynamics have shifted since the assassination attempt on President Trump and the coronation of Kamala Harris. What's the state of the race since Biden dropped out? Who is the most dangerous (for Republicans) VP that Kamala could choose? What does JD Vance bring to the table for Trump? What are the prospects for Republicans in the House and Senate? As good as the polling looks now, Frank and Kristen explain why Republicans should run through the tape and not be overly confident. Kristen Soltis Anderson is a pollster, speaker, commentator, and author of The Selfie Vote: Where Millennials Are Leading America (And How Republicans Can Keep Up). She is Founding Partner of Echelon Insights, an opinion research and analytics firm that serves brands, trade associations, nonprofits, and political clients. Through her work at Echelon, she regularly advises corporate and government leaders on polling and messaging strategy, and has become one of the foremost experts on the Millennial generation. She also leads focus groups for The New York Times' opinion section “America in Focus” series. Follow her on X at @KSoltisAnderson and read her Substack here: kristensoltisanderson.substack.com/ Dr. Frank Luntz has written, supervised, and conducted more than 2,500 surveys, focus groups, ad tests, and dial sessions in more than two dozen countries on six continents over the past 20 years. His political knowledge and skills are recognized globally, and he has served as an election consultant and commentator in Canada, Britain, Ireland, Germany, Austria, the Netherlands, Australia, Venezuela, and Ukraine. Follow him on X at @FrankLuntz.

MattKUltra and Roswell return to discuss the heartthrob-turned-rocker-turned-guru: Jared Leto. We touch on his strange career trajectory and obscured beginnings and see what info we can glean from his family history. Furthermore, we discuss his strange relationship to his “Echelon” fanbase, his bands use of cryptic runes, and the funding and circumstances of the band in relation to their actual sales performance. Finally we discuss what powers could benefit from pushing this specific pop-throb prince and what one may be able to gain by having a pop star in their pocket.

Recorded June 20, 2024 ***NOTE: The s-bomb is dropped a couple of times during this episode*** Welcome to the last episode before our summer hiatus! The podcast will resume September 2nd, 2024. In this episode...... [0:45] Meredith's bidding doers [4:00] The 4th of July....in Canada, and, fireworks and sparklers [10:00] Sharkside of the Moon and other things we're watching/have watched [15:46] Echelon cruise and swimming with pigs [16:27] Hockey update...or not [17:10] Echelon news (upcoming rides) [17:56] Abe gets a package in the mail [27:38] Some sad news [29:44] Meredith found someone to do her bidding [35:19] Special correspondent Kelli Quinn (Pig Mom) reporting from the Spartan race [47:04] Did You Know

Drs. John Sweetenham and Marc Braunstein discuss practice-changing studies in hematologic malignancies that were featured at the 2024 ASCO Annual Meeting, including the ASC4FIRST trial in chronic myeloid leukemia and IMROZ and CARTITUDE-4 in multiple myeloma.  TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News Podcast. On today's episode, we'll be discussing practice-changing abstracts and other key advances in hematological malignancies that were featured at the 2024 ASCO Annual Meeting. Joining me for this discussion is an old friend, Dr. Marc Braunstein, a hematologist and oncologist from the NYU Langone Perlmutter Cancer Center.  Our full disclosures are available in the transcript of this episode. Marc, it's great to have you back on the podcast again. There were some important studies in the heme space at the Annual Meeting this year, and we're very pleased that you're able to share your takeaways.  Dr. Marc Braunstein: Thank you, John. It's great to be back again. Dr. John Sweetenham: Let's start out, Marc, with LBA6500. This abstract reports the primary results of the ASC4FIRST trial, and this was a trial comparing asciminib with investigator selected tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia. Could you tell us a little about the trial and how you think it's going to impact clinical practice? Dr. Marc Braunstein: Absolutely. So, asciminib is an oral tyrosine kinase of the ABL kinase domain. As we know in CML, the BCR-ABL translocation is characteristic of the disease, and asciminib is approved for chronic phase CML with a T315I resistance mutation or for patients who have received 2 or more prior lines of therapy. So the ASC4FIRST trial was a randomized trial of 405 patients with newly diagnosed chronic phase CML who are randomized one to one to receive either asciminib at 80 milligrams once daily, or investigator's choice of a first generation TKI imatinib or one of three second generation TKIs nilotinib, dasatinib, or bosutinib. The primary endpoint of the study was the major molecular response, or MMR, at 48 weeks. Pretty much, the study met its primary endpoint with a 67% rate of MMR at 48 weeks, with asciminib versus 49% in patients treated with the investigator's choice of TKI. And in addition, the major molecular remission or MMR of 4.5, which is a deep remission, those rates were higher as well, with asciminib versus investigator's choice at a rate of 39% versus 21% when comparing the groups. Furthermore, when we looked at toxicity, there were fewer grade 3 or higher adverse events, with the asciminib at 38% versus either 44% with the first generation, or 55% with the second generation TKI, and fewer discontinuations as well with asciminib.  So I think this abstract is practice-changing. I think it offers compelling data to use asciminib upfront for chronic phase CML. Those who don't agree with that sentiment might argue that we want to see longer term follow up. There's a planned follow-up at 96 weeks. We would want to see the rate of progression to acute myeloid leukemia and of course overall survival as well. But I think the abstract certainly shows an improvement in outcomes with asciminib versus our current array of TKIs. Dr. John Sweetenham: Yeah, I think it certainly is, at least at minimum, potentially practice changing. I agree with you. Just one question, and this may be a little bit speculative, but do you have any thoughts about treatment free survival with asciminib and how that might line up against some of the other TKIs? Dr. Marc Braunstein: Yeah, that's a great question. The abstract did not necessarily address that, patients were treated until progression, but we know that with the current landscape of TKIs, that in patients who have achieved a deep MR of 4 or 4.5 for at least 2 years who discontinue their TKI, the rate of relapse is about 50%. The current study, the ASC4FIRST, doesn't address that, but I think it's a really good question about whether, for those patients who have achieved a deep remission, whether they can eventually stop asciminib down the line. Dr. John Sweetenham: Yeah, I guess it's one of those ‘watch this space' things.  So we'll see how the data mature out. And let's move on to what I think is another potentially practice-changing study, at least in certain parts of the world. And that's [the] LBA7000 study in classical Hodgkin lymphoma. As you remember, this was a German Hodgkin lymphoma study group trial which looked at the tolerability and efficacy of a novel regimen, BrECADD versus eBEACOPP for patients with advanced stage classical Hodgkin lymphoma in their study, which is known as GHSG HD21. Can you give us your thoughts and take home messages from this trial? Dr. Marc Braunstein: Yeah, John, absolutely. So the German HD21 study is a phase 3 study of 1,500 patients with classical Hodgkin lymphoma. The majority were stage 3 or 4, 84%, that compared two regimens BEACOPP to BrECADD. The major difference between these 2 groups being that the newer BrECADD regimen swaps out bleomycin for brentuximab vedotin, which is an anti-CD30 antibody drug conjugate. Also, in the BrECADD regimen they eliminate vincristine that's incorporated into BEACOPP. Those are kind of the global differences between these 2 regimens. And when comparing these, they looked at the primary endpoint of progression-free survival. Of note, in this study there was a PET adjusted approach where if patients achieved interim PET negativity after 2 cycles, that was followed by an additional 2 cycles of their treatment as opposed to 4 cycles if they were PET positive after the initial 2 cycles of their respective treatment. And of note, there were similar rates of PET2 negativity between both arms, about 58% in both arms.  So at a median follow-up of 48 months, the 4-year progression-free survival was significantly better with the brentuximab containing BrECADD regimen at 94% versus 91% with a hazard ratio of 0.66. And the overall survival of the BrECADD arm was 98.6%, which is very high and impressive. The 4-year overall survival was similar between the arms at around 98%, but of note, there were fewer severe adverse events with BrECADD, the brentuximab containing arm versus BEACOPP at about 42% versus 59% and interestingly less peripheral neuropathy with the brentuximab containing BrECADD. So we're doing extremely well in treating advanced stage classical Hodgkin lymphoma. So the bar is set very high. But in this study, the rates of progression-free survival and overall survival are very impressive.  While these intensive regimens tend to be used outside of the U.S., there are several notable benefits of the study, including greater than 50% PET2 negativity and high rates of progression-free survival at 4 years. In discussing this abstract, it's worth noting that there are other competing regimens, if you want to call it that, that are more commonly used in the U.S. So the ECHELON-1 study looked at brentuximab AVD compared with ABVD with bleomycin and it was a 94% versus 89% 6-year overall survival rate favoring the brentuximab containing A+AVD regimen. And lastly, more recently, the SWOG S1826 study that hasn't been published but was presented in abstract form looked at nivolumab AVD versus brentuximab AVD at a median follow up of 12 months showed a progression-free survival of 94% versus 86%. And that study still has yet to be published and needs to mature. But both of those regimens are in the NCCN guidelines. So, we're definitely pushing the bar higher in terms of improving responses in treating advanced classical Hodgkin lymphoma. Dr. John Sweetenham: I think that there's no question that these results from BrECADD are very impressive. But I'm taken back to what I think has been a kind of philosophic discussion in Hodgkin lymphoma now for a number of years about balancing disease control and efficacy against the potential short-term and long-term toxicity of the regimens, particularly when you have very effective salvage therapies for those patients who may suffer a relapse. So I think that this is a discussion over whether you take a very intensive, upfront approach to Hodgkin lymphoma versus something that may be less and slightly less intensive. I suspect that's a discussion that's going to continue for a long time. I don't know what you feel, but my own feeling about this is that this study will likely have a major influence over treatment of Hodgkin lymphoma, particularly in western Europe. Less likely in the US.., I would think. I don't know what your thoughts about that are. Dr. Marc Braunstein: Well, it's a great question. In SWOG S1826, that study did include pediatric patients. In HD21, the median age was 31 and did not include pediatric patients. So I think we have to be selective in terms of fitness and which patients may be better suited for different regimens. But I think what all these studies show is certainly when we incorporate novel immunotherapies, whether it's brentuximab vedotin, nivolumab, we improve progression-free survival and even overall survival. Dr. John Sweetenham: Absolutely.  So let's shift gears now and take a look at Abstract 7500, the IMROZ study. This was the study of isatuximab, bortezomib, lenalidomide and dexamethasone versus VRD alone for transplant ineligible patients with newly diagnosed multiple myeloma. I know we discussed this in our preview podcast a few weeks back, Marc, but I just wonder now, having seen the data in more detail, what do you think of the important takeaways? And again, are we looking at a new standard of care? Dr. Marc Braunstein: You know, there are many standards of care in multiple myeloma, but we're always looking to make improvements on the regimens we have at our disposal. So, just to recap, IMROZ is a phase 3 randomized study of the anti-CD38 monoclonal antibody isatuximab with the backbone of bortezomib, lenalidomide, dexamethasone or VRD versus VRD alone, specifically, in transplant ineligible newly diagnosed multiple myeloma patients age less than 80. They studied 446 patients in this study, randomized 3 to 2 to Isa-VRD versus VRD alone, with the primary endpoint of progression free survival. Now, similar to other studies where they included a monoclonal antibody up front, the study met its primary endpoint of improving progression-free survival with the quad regimen containing the monoclonal antibody isatuximab versus VRD alone.  So what was interesting about the study, it's really the first of its kind to be presented that specifically looked at transplant ineligible patients, which is presumably a less fit or perhaps more frail population that wouldn't go on to consolidation with stem cell transplant. And in this study, the progression-free survival at 5 years was 63% versus 45%, clearly superior when you included isatuximab. And the rates of complete remission and MRD negativity were all significantly improved, too. However, that was also met with slightly more grade 3 or higher treatment emergent adverse events, 92% versus 84% in the control arm. There are also 11% grade 5 treatment emergent adverse events with the isatuximab group versus 5.5% with VRD alone. Although there was no major difference in treatment discontinuation. One small caveat worth noting, too, is that high-risk patients in this study, when presented at ASCO, did not necessarily show a difference in benefit, although there wasn't necessarily a detriment either.  So, John, I think that clearly quadruplet regimens are superior in outcomes of efficacy to triplets, even in transplant-ineligible patients. But I think we have to tailor these treatments to individual patients because I think when it comes to transplant-ineligible patients, it's a spectrum of patients who may be more or less fit for quad regimens versus triplet regimens. It's also worth noting, though, that in this study, the patients are really only getting a quad regimen for 4 cycles. They get their Isa-VRD, and then you drop the bortezomib.  So when we think about quads, it's not that they're getting the quad regimen indefinitely, it's really for the induction cycles. But still, I think we have to be aware of potential safety issues. Dr. John Sweetenham: Okay, great. And let's stay on the theme of multiple myeloma, Marc, and talk a little bit about Abstract 7504, which was a subgroup analysis of the CARTITUDE-4 study. This is a report on the use of ciltacabtagene autoleucel versus standard of care in patients with functional high risk multiple myeloma. Can you give us your thoughts on this and maybe put it into a bit of context for us?  Dr. Marc Braunstein: Absolutely, John. It's really a great time to be in the field of multiple myeloma. We're making tremendous progress, but when we think about one of the unmet needs, it's just consistently the high-risk patients who have shorter responses and are at higher risk for poorer outcomes. Just to review, cilta-cel is one of the 2 available anti-BCMA CAR T-cell products available for the treatment of relapsed or refractory multiple myeloma. Very recently, the FDA approved cilta-cel for lenalidomide refractory patients after 2 or more prior lines of therapy based on the CARTITUDE-4 study, which was published by San-Miguel and colleagues in New England Journal of Medicine in July 2023. And that study randomized 419 patients with multiple myeloma with 1 to 3 prior lines of therapy to receive either cilta-cel or physician's choice of standard of care, which was either 1 of 2 triplet regimens, a pomalidomide, bortezomib, dexamethasone or daratumumab, pomalidomide and dexamethasone. It's worth noting that about 25% of the patients in the CARTITUDE-4 study had prior anti-CD38 antibody treatment previously and the carfilzomib was not included in one of the standard-of-care arms, and we know that those regimens containing carfilzomib do increase survival in relapsed myeloma.  Nevertheless, the primary outcome of progression-free survival was not reached in the CAR T-cell arm versus 11.8 months in the standard-of-care arm, with a significant reduction in progression of 74%. So clearly a positive study and CAR T-cell therapy is included in the NCCN guidelines for patients who have an early relapse from their myeloma. The current abstract by Costa et al focused specifically on a subgroup of 79 patients from CARTITUDE-4 in second line of treatment and looked at what they called functional high-risk myeloma, defined as progression of disease within 18 months of initial treatment or after stem cell transplant. Again, the study showed a retained benefit of cilta-cel with significant improvement in progression-free survival either not reached or 12 months with the control standard of care arm, as well as complete remission rate and rates of MRD negativity of 65% versus 10% in the control.  The overall survival outcome was still immature and not presented. Nevertheless, cilta-cel is clearly superior to standard-of-care triplet regimens. I think that for patients with high risk, they clearly derive a benefit from CAR T-cell therapy if they have short progression-free survival after initial therapy.  Dr. John Sweetenham: Thanks, Marc. So let's round this out by talking about another area of unmet need, I guess in a way in a difficult to treat patient group. And that's Abstract 7007, the SYMPATICO study. This is a study which looks at the efficacy and safety of ibrutinib and venetoclax in patients with mantle cell lymphoma who had a mutated TP53. Can you just briefly review this for us and tell us what you think we should be taking away from this studys? Dr. Marc Braunstein: So, mantle cell lymphoma typically has an aggressive behavior, but the subgroup of patients with a P53 mutation tend to have the poorest outcomes and do represent an area of unmet need. Although BTK inhibitors are making important improvements in mantle cell lymphoma, they have yet to be approved in newly diagnosed mantle cell lymphoma. Acalibutinib and zanubrutinib are FDA-approved BTK inhibitors for previously treated mantle cell lymphoma. Ibrutinib was withdrawn from the market in the U.S. for mantle cell lymphoma. Dr. Michael Wang's group presented late-breaking data from the phase 3 SYMPATICO trial at ASH 2023, in which 267 patients with relapsed refractory mantle cell lymphoma were randomized to receive either ibrutinib plus the BCL2 inhibitor venetoclax or ibrutinib plus placebo after 1 to 5 prior lines of therapy. And that study showed a 32 versus 22 months progression-free survival at a median follow up of 51 months. The current abstract, also by Dr. Wang and colleagues, looked at the subgroup of patients who had a P53 mutation and included an open label cohort of 44 patients in the first line of treatment and a relapse refractory cohort of 75 patients, and compared this subgroup of patients with P53 mutation to those without. When we look at the outcomes, the patients who did not have a P53 mutation clearly did better in terms of progression-free survival being not reached in first-line treatment compared to 22 months progression-free survival in those patients with first-line [treatment] with a P53 mutation. As well as in the relapsed refractory setting, the PFS without the P53 mutation was 47 months versus 21 months with the mutation. However, when you look at these patients treated with ibrutinib and venetoclax comparing whether they got treated in first line or the relapse refractory setting, the overall response rates are very similar at about 80% to 90% and the CR rates were very similar at about 55% to 58%, which to me suggests that although patients with P53 mutation do worse than those without it, whether they're treated in the first-line or the relapse setting with this combination of venetoclax, they tend to do somewhat similar, suggesting that you can overcome resistance to prior therapy in the relapse setting. So I think further data are certainly warranted to explore the role of combination therapies that include novel agents such as BTK inhibitors in the first line setting.  It's worth noting that the TRIANGLE study was recently published, and this study looked at including ibrutinib at various phases, including at induction in combination with intensive chemotherapy and during the maintenance phase. And that study showed encouraging outcomes in patients who received ibrutinib even without stem cell transplant compared to those who received stem cell transplant. So the role of BTKIs in mantle cell lymphoma is certainly evolving, and I think it offers a very effective intervention without the same kind of toxicities we see with cytotoxic chemotherapy that's traditionally used in mantle cell lymphoma. But I think the subgroup of patients with P53 mutation in this disease still represent an area of unmet need that unfortunately have worse outcomes. But novel agents may be able to overcome some of those adverse outcomes. Dr. John Sweetenham: Yeah, I agree. I think these are intriguing data, and obviously it needs more follow-up and probably more prospective studies. But nevertheless, I think there are some signals there for sure that need to be followed up on.  Marc, as always, it's great to have your insights on key advances in the heme space from ASCO. An important year this year, and we really appreciate your time and effort in sharing with us your thoughts on what we've learned this year. So thank you as always. Dr. Marc Braunstein: My pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstract discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. Marc Braunstein  @docbraunstein    Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS   

HOUR 1 - Greg invites Courtney to swim at Echelon. Coco promptly spills the beans John Rahm is quickly becoming the villain of the golf world Wiggy says the Celtics should lock up and pay Mazzulla now

Josh Zollweg joins us and Sonic does him dirty, Tom gets his USP and a ripoff, Robert gets the new Defender XL, then we give Springfield Armory some advice on how to sell the Echelon. ---- Show Sponsors: Rune Tactical Dominate Defense W-74 Guide Rods Youtube Channel: https://www.youtube.com/@paracastfirearmspodcast905 Telegram: https://t.me/paracastpodcast Patreon: patreon.com/user?u=16370931

Happy Memorial Day to our American friends! In this episode, Meredith recaps her visit to The Flying Pig Bed 'n Breakfast*, and all the fun things she did while in Missouri. We have some cruise news, as well as our usual segments to round out this episode. 00:55 Meredith thinks she's a princess! 2:25 Meredith recaps her Missouri trip 7:59 Aquarium yoga 10:36 Watcha listenin' to? 14:40 Hillbilly Handfishin' (and yes - we googled it) 19:04 Color Guard, Harry Potter, and Meredith 22:23 Is Abe a robot? 24:06 Echelon news - Who's cruisin' who? 28:47 Meredith, the world traveller 34:33 More Echelon news 37:35 Do you chunk or chuck? 40:26 Fun LB names 46:24 Shoutouts 51:10 Did You Know? *Disclaimer - the Flying Pig Bed 'n Breakfast is not an actual Bed 'n Breakfast

Peloton “pauses” Sean Combs music. Peloton launches global refinancing.  Peloton creates mindful music playlist.  Peloton hit the goal for Project Healthy Minds.  Tweaks to the website.  Peloton sued for collapsing bike.  MetPro/Angelo - Struggling to find the balance in a calorie deficit.  Robin Arzon and Benny Adami are doing a Hyrox race.  Susie Chan has a book event at PSL.  Jermaine Johnson participated in Knife Crime Awareness Week.  Jon Hosking injured ankle has escalated to a boot.  Helper Bee Nikki takes us to Peloton High. The latest artist series features Rolling Stones.  Is someone creating a knock-off of…Echelon?  TCO Top 5.  This Week At Peloton.  There are new Yoga and Meditation Challenges for June.  Lululemon releases its Pride Collection.   Birthdays - Ash Pryor (5/20), Jess King (5/29) All this plus our interview with Jose Quintero! Love the show? Subscribe, rate, review, and share! https://www.theclipout.com Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode Aaron is joined by Immanuel Martinez, Public Works Division Manager at Sunland Asphalt & Construction,LLC. Although Sunland does some pretty awesome work all throughout Arizona and other parts of the southwest, in this episode Aaron focuses on a project of sunland's that he saw personally last year in the southeast.  Without giving too much away, it's in Miami and features some very fast vehicles. Aaron and Immanuel discuss the intricacies of such specialized asphalt paving. Working with unique materials, tight tolerances and other contractors on site all while being a nation's distance away from the company's HQ, makes for some pretty interesting circumstances. To learn more about Immanuel and Sunland stay tuned for this fascinating episode all about asphalt.  **UPDATE** Dirt Talk is STOKED to announce Ariat as our first official sponsor for the year! They make world-class footwear and workwear that we see on every job site we visit, and their folks are just as great as their products. Dirt Talk listeners can receive 10% off their first order with Ariat by clicking here or visiting Ariat.com/dirttalk. If you have any questions or feedback, email the Dirt Talk crew at dirttalk@buildwitt.com. Stay Dirty!

Recorded May 9, 2024 This week, Meredith and Abe chat with triathlete and former figure skater, Pam Rosenberg (aka PamChicago). To say the hour flew by is an understatement! Pam does so much for the Echelon community, that we just couldn't pass up an opportunity to get to know her better!

This week we're joined by Shae Primus, Founder of Upper Echelon Matchmaking. Thanks to our sponsors!Try VIIA Hemp! https://bit.ly/3J1UitO and use code COCKTALES!Control Body Odor ANYWHERE with @lumedeodorant and get $5 off off your Starter Pack (that's over 40% off) with promo code COCKTALES at https://www.lumedeodorant.com ! #lumepodCheck out some of our other sponsors here: https://linktr.ee/cocktalesadsFollow Us@cocktalespodcast@kikisaidso@coffeebeandeanWant to sponsor or collaborate with us? contact us at sales@cocktalespod.comInterested in being a guest? Please contact addie@cocktalespod.com and include your information, what makes you an interesting guest, and any relavant links!For all promo codes and links for promotions in the episode, follow this link: https://linktr.ee/cocktalesadsContact Us! Advice: advice@cocktalespod.comCocktales: cocktales@cocktalespod.comWeird Sex: weirdsex@cocktalespod.comLive Show Sponsorship: sales@cocktalespod.comGuest Request/ General Inquiries info@cocktalespod.comGet your Vesper2https://www.lovecrave.com/products/vesper2/?aop=cocktalesGet Your Merch & Order Your Card GamePurchase Merch And Card Game at www.imcurioustoknow.comGet Klassy Baste! Learn to Cook with Kiki www.klassybaste.comJoin Kiki's Book Club www.patreon.com/kikisaidsoTravel with Kiki! We're going to St. Lucia Feb 15-20! Use code KIKI for $100 off! Payment plans available https://10vacationdays.com/ Travel With Medinah! https://linktr.ee/MedinahMonroePurchase Medinah's Coffee Mug! www.medinahmonroe.comInterested in sponsoring? Contact sales@cocktalespod.com today!This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/2818687/advertisement

Pollster Kristen Soltis Anderson returns to give Rep. Crenshaw her insights into Trump vs DeSantis, how abortion is affecting the GOP's election prospects, good and bad candidate messaging strategies, and much more. What should DeSantis do if he had a time machine? How did Republicans get caught off guard by the Roe v Wade backlash and is there any hope to convince Gen Z to become pro-life? What effect is the political consulting industry having on candidate quality and the populist echo chamber of social media? They also discuss how to craft accurate voter surveys, what went wrong with the 2022 midterms, and Trump's chances of defeating Biden in 2024. Kristen Soltis Anderson is a pollster, speaker, commentator, and author of The Selfie Vote: Where Millennials Are Leading America (And How Republicans Can Keep Up). She is Founding Partner of Echelon Insights, an opinion research and analytics firm that serves brands, trade associations, nonprofits, and political clients. Through her work at Echelon, she regularly advises corporate and government leaders on polling and messaging strategy, and has become one of the foremost experts on the Millennial generation. She also leads focus groups for The New York Times' opinion section “America in Focus” series. Follow her on X at @KSoltisAnderson and read her Substack here: kristensoltisanderson.substack.com/